MX2021003169A - Metodos para purificar anticuerpos multiespecificos, heterodimericos. - Google Patents

Metodos para purificar anticuerpos multiespecificos, heterodimericos.

Info

Publication number
MX2021003169A
MX2021003169A MX2021003169A MX2021003169A MX2021003169A MX 2021003169 A MX2021003169 A MX 2021003169A MX 2021003169 A MX2021003169 A MX 2021003169A MX 2021003169 A MX2021003169 A MX 2021003169A MX 2021003169 A MX2021003169 A MX 2021003169A
Authority
MX
Mexico
Prior art keywords
methods
multispecific antibodies
purifying heterodimeric
heterodimeric
purifying
Prior art date
Application number
MX2021003169A
Other languages
English (en)
Inventor
Ute Schellenberger
Brett Jorgensen
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of MX2021003169A publication Critical patent/MX2021003169A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan métodos para purificar anticuerpos multiespecíficos, heterodiméricos a partir de una disolución.
MX2021003169A 2018-09-21 2019-09-20 Metodos para purificar anticuerpos multiespecificos, heterodimericos. MX2021003169A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862734566P 2018-09-21 2018-09-21
US201862742821P 2018-10-08 2018-10-08
PCT/US2019/052199 WO2020061478A2 (en) 2018-09-21 2019-09-20 Methods for purifying heterodimeric, multispecific antibodies

Publications (1)

Publication Number Publication Date
MX2021003169A true MX2021003169A (es) 2021-08-11

Family

ID=68240802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003169A MX2021003169A (es) 2018-09-21 2019-09-20 Metodos para purificar anticuerpos multiespecificos, heterodimericos.

Country Status (12)

Country Link
US (1) US20210355215A1 (es)
EP (1) EP3853253A2 (es)
JP (1) JP2022501357A (es)
KR (1) KR20210063354A (es)
CN (1) CN112839959A (es)
AU (1) AU2019343053A1 (es)
BR (1) BR112021004680A2 (es)
CA (1) CA3113057A1 (es)
IL (1) IL281570A (es)
MX (1) MX2021003169A (es)
SG (1) SG11202102713TA (es)
WO (1) WO2020061478A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
CR20220578A (es) * 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
AU2018392088A1 (en) 2017-12-22 2020-08-13 Teneobio, Inc. Heavy chain antibodies binding to CD22
AU2020291938A1 (en) 2019-06-14 2022-01-20 Teneobio, Inc. Multispecific heavy chain antibodies binding to CD22 and CD3
EP4121172A1 (en) * 2020-04-29 2023-01-25 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
CN114539417A (zh) * 2020-11-26 2022-05-27 盛禾(中国)生物制药有限公司 一种有效去除双特异性抗体同源二聚体的层析纯化工艺
CN117242095A (zh) * 2021-04-23 2023-12-15 和铂医药(上海)有限责任公司 一种双特异性抗体的纯化方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
DE19836213A1 (de) * 1998-08-11 2000-02-24 Gerhard Harry Scholz Verfahren zur Elution von Biomolekülen von Chromatographie-Materialien
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
AU2006312148B2 (en) 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
EP2815768A3 (en) 2006-04-05 2015-01-14 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP3041865A2 (en) * 2013-09-03 2016-07-13 NovImmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
AU2017298984B2 (en) * 2016-07-22 2023-08-31 Amgen Inc. Methods of purifying Fc-containing proteins
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio Inc anticorpos apenas de cadeia pesada anti-bcma

Also Published As

Publication number Publication date
WO2020061478A3 (en) 2020-04-30
BR112021004680A2 (pt) 2021-08-31
JP2022501357A (ja) 2022-01-06
CN112839959A (zh) 2021-05-25
EP3853253A2 (en) 2021-07-28
IL281570A (en) 2021-05-31
AU2019343053A1 (en) 2021-04-15
CA3113057A1 (en) 2020-03-26
WO2020061478A2 (en) 2020-03-26
KR20210063354A (ko) 2021-06-01
SG11202102713TA (en) 2021-04-29
US20210355215A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
MX2021003169A (es) Metodos para purificar anticuerpos multiespecificos, heterodimericos.
GB202101720D0 (en) Sars-cov-2 (sars2, covid-19) antibodies
MX2021006235A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12018501159A1 (en) Composition and methods for immunooncology
MX2018006148A (es) Inhibidores de cxcr2.
PH12017501042A1 (en) Anti-cd38 antibodies for treatment of acute myeloid leukemia
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2019008065A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
MX2020003497A (es) Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
PH12016501366A1 (en) Novel anti-baff antibodies
MX2023006415A (es) Anticuerpos, usos y metodos.
MY175418A (en) Compositions comprising anti-cd38 antibodies and carfilzomib
MX2017013100A (es) Proceso para aislar y purificar ambrox.
CR20220156A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
MX2020007742A (es) Procesos para preparar fluorocetolidos.
MX2019010492A (es) Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado.
MX2021003180A (es) Métodos y kits para preparar sangre entera con inactivación de patógenos.
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
MX2021000797A (es) Anticuerpos agonistas de cd226.
MX2018004005A (es) Ensayo de potencia celular.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
CL2016002256A1 (es) Un proceso mejorado para la preparación de exametazima